This trial is testing whether a computer-driven system for dosing a medication is more effective and safer than standard dosing for Crohn's disease.
0 Primary · 12 Secondary · Reporting Duration: week 14, week 26, and week 52
Active Control
Experimental Treatment
196 Total Participants · 3 Treatment Groups
Primary Treatment: Infliximab · No Placebo Group · Phase 4
Age Any Age · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: